Pasithea Launches $60M Offering Amidst Nasdaq Price Discrepancy

TL;DR

**Pasithea's offering is a high-risk bet on future drug development, with a significant pricing premium over current market value that screams dilution for existing shareholders.**

AI Summary

Pasithea Therapeutics Corp. (KTTAW) is conducting an S-1/A offering to sell up to 75,000,000 shares of common stock and up to 75,000,000 pre-funded warrants, aiming to raise capital for its clinical-stage biotechnology operations. The assumed public offering price for common stock is $0.80 per share, while pre-funded warrants are priced at $0.799, exercisable at $0.001 per share. This offering, managed by H.C. Wainwright & Co., LLC on a reasonable best efforts basis, has no minimum offering requirement and will terminate by December 31, 2025. The company's primary focus is on developing PAS-004, a MEK inhibitor for CNS disorders, RASopathies, and MAPK pathway-driven tumors, for which the FDA cleared an IND in December 2023 for a Phase 1 trial. Pasithea is an 'emerging growth company' and 'smaller reporting company,' indicating reduced reporting requirements. The offering price of $0.80 per share is significantly higher than the common stock's closing price of $0.4876 on November 25, 2025, suggesting potential dilution for existing shareholders.

Why It Matters

This S-1/A filing is critical for Pasithea Therapeutics as it seeks to raise up to $60 million to fund its clinical development, particularly for its lead candidate PAS-004. For investors, the offering at $0.80 per share, significantly above the recent market price of $0.4876, presents a complex valuation challenge and potential for immediate dilution. Employees and customers will be impacted by the company's ability to secure this funding, which directly supports ongoing research and development in competitive fields like CNS disorders and oncology. The success of this capital raise will determine Pasithea's capacity to advance its pipeline and compete with larger, more established biotechnology firms.

Risk Assessment

Risk Level: high — The offering involves a high degree of risk, as explicitly stated on page 6 of the prospectus. Pasithea Therapeutics is a clinical-stage biotechnology company with a 'lack of operating history' and expects to 'incur significant operating losses for the foreseeable future and will need significant additional capital.' Furthermore, the offering price of $0.80 per share is substantially higher than the common stock's closing price of $0.4876 on November 25, 2025, indicating potential immediate downside for new investors if the market price does not converge.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Pasithea's long-term clinical prospects and financial stability before considering this offering. Given the significant premium over the current market price, potential investors should wait for the actual offering price to be determined and assess the impact of dilution on existing shares. Consider the company's ability to achieve clinical milestones for PAS-004 before committing capital.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 75,000,000 — Shares of Common Stock Offered (Maximum number of shares offered in this S-1/A)
• 75,000,000 — Pre-Funded Warrants Offered (Maximum number of pre-funded warrants offered)
• $0.80 — Assumed Public Offering Price per Share (Significantly higher than the market price of $0.4876 on November 25, 2025)
• $0.799 — Assumed Public Offering Price per Pre-Funded Warrant (Reflects the $0.001 exercise price for each warrant)
• $0.001 — Exercise Price per Pre-Funded Warrant (Low exercise price makes warrants attractive for certain investors)
• $0.4876 — Common Stock Closing Price (Nov 25, 2025) (Indicates a substantial premium for the offering price compared to recent market value)
• 5% — Placement Agent Warrants (Percentage of shares sold that the placement agent can purchase at $1.00 per share)
• December 31, 2025 — Offering Termination Date (The deadline for the 'reasonable best efforts' offering)
• December 2023 — FDA IND Clearance for PAS-004 (Key regulatory milestone for their lead product candidate)
• Phase 1 — Clinical Trial Stage for PAS-004 (Indicates early-stage development for their lead candidate)

Key Players & Entities

• Pasithea Therapeutics Corp. (company) — Registrant and issuer of securities
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for the offering
• Tiago Reis Marques (person) — Chief Executive Officer of Pasithea Therapeutics Corp.
• James O’Grady, Esq. (person) — Legal counsel from Lowenstein Sandler LLP
• Rakesh Gopalan, Esq. (person) — Legal counsel from Troutman Pepper Locke LLP
• David S. Wolpa, Esq. (person) — Legal counsel from Troutman Pepper Locke LLP
• U.S. Food and Drug Administration (FDA) (regulator) — Cleared IND for PAS-004
• $0.80 (dollar_amount) — Assumed public offering price per share of common stock
• $0.799 (dollar_amount) — Assumed public offering price per Pre-Funded Warrant
• $0.4876 (dollar_amount) — Closing price of common stock on Nasdaq on November 25, 2025

FAQ

Risk Factors

• Inability to Raise Sufficient Capital [high — financial]: The company is seeking to raise capital through this offering, but there is no minimum offering requirement. If the offering is not successful, Pasithea may not be able to fund its operations, including the development of PAS-004, which could lead to a significant negative impact on its business and prospects.
• Dilution from Offering Price Premium [medium — financial]: The offering price of $0.80 per share is substantially higher than the recent closing price of $0.4876 on November 25, 2025. This significant premium could lead to substantial dilution for existing shareholders if the stock price does not appreciate to meet the offering price.
• Dependence on Lead Product Candidate [high — operational]: Pasithea's success is heavily reliant on the development and commercialization of PAS-004. The company has limited resources and is in the early stages of clinical development (Phase 1 trial cleared in December 2023). Any setbacks in the development or regulatory approval of PAS-004 could severely impact the company.
• Clinical Trial Risks and Delays [high — regulatory]: The company is conducting a Phase 1 trial for PAS-004. Clinical trials are inherently risky and can face delays due to patient recruitment, unexpected side effects, or regulatory hurdles. Failure to successfully complete clinical trials could prevent the company from bringing PAS-004 to market.
• Competition in CNS Disorders and Oncology [medium — market]: The markets for CNS disorders, RASopathies, and MAPK pathway-driven tumors are highly competitive, with many established pharmaceutical companies and emerging biotechs developing therapies. Pasithea faces significant competition, and its ability to differentiate PAS-004 will be critical.
• Limited Operating History and Profitability [high — financial]: As an emerging growth company, Pasithea has a limited operating history and has not yet generated significant revenue or achieved profitability. Its ability to sustain operations and fund future development depends heavily on successful capital raises.
• Reliance on Key Personnel [medium — operational]: The success of Pasithea's development programs depends on its ability to attract and retain qualified scientific and management personnel. The loss of key individuals could disrupt its operations and strategic direction.
• Placement Agent Warrants [low — financial]: The placement agent, H.C. Wainwright & Co., LLC, may purchase warrants to purchase up to 5% of the shares sold in the offering at $1.00 per share. This could lead to further dilution for existing shareholders upon exercise.

Industry Context

Pasithea Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapies for CNS disorders, RASopathies, and MAPK pathway-driven tumors. This space is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Key trends include advancements in targeted therapies and precision medicine, but also intense competition from established pharmaceutical giants and numerous emerging biotechs.

Regulatory Implications

The company's lead candidate, PAS-004, has received FDA IND clearance for a Phase 1 trial, a positive step. However, the path through clinical trials (Phase 1, 2, and 3) and subsequent FDA approval is lengthy, costly, and fraught with potential setbacks. Failure at any stage can halt development, and ongoing compliance with evolving regulatory standards is critical.

What Investors Should Do

1. Evaluate the risk of dilution
2. Assess the clinical development risk
3. Monitor capital raising efforts
4. Consider the competitive landscape

Key Dates

• 2023-12-01: FDA IND Clearance for PAS-004 — This milestone allows Pasithea to commence its Phase 1 clinical trial, a crucial step in the drug development process for its lead candidate.
• 2025-12-31: Offering Termination Date — This is the deadline for the 'reasonable best efforts' offering, indicating the timeframe within which the company aims to secure capital from this S-1/A filing.

Glossary

S-1/A

An amended registration statement filed with the SEC, typically used by companies going public or making subsequent offerings to provide updated or corrected information. (This filing details Pasithea's current offering, its business strategy, risks, and financial information.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase shares at a nominal exercise price (here, $0.001), effectively providing immediate ownership of the underlying share upon purchase of the warrant. (These are offered alongside common stock, providing investors with a potentially more immediate stake and the company with capital, while being attractive due to the low exercise price.)

MEK inhibitor

A type of drug that blocks the activity of MEK (mitogen-activated protein kinase kinase), a protein involved in cell signaling pathways that can drive cancer growth. (PAS-004, Pasithea's lead candidate, is a MEK inhibitor, targeting specific pathways implicated in various diseases.)

IND Clearance

Investigational New Drug clearance from the FDA, which permits a company to administer an experimental drug to humans in clinical trials. (The IND clearance for PAS-004 is a critical regulatory step, validating the drug's potential for human testing and advancing its development.)

Emerging Growth Company

A designation under the JOBS Act for companies with less than $1.235 billion in annual gross revenue, allowing for reduced regulatory and reporting requirements. (Pasithea's status as an EGC means it has fewer disclosure obligations, which can impact the depth of information available to investors.)

Smaller Reporting Company

A company that meets certain criteria related to public float and annual revenue, also benefiting from scaled-down SEC disclosure requirements. (Similar to EGC status, this designation simplifies reporting, potentially limiting the detail provided in filings.)

Reasonable Best Efforts

An underwriting commitment where the underwriter agrees to use its best efforts to sell the securities but does not guarantee the sale of all offered securities. (This indicates that H.C. Wainwright & Co., LLC is not obligated to purchase any unsold shares, meaning the offering's success is not guaranteed.)

RASopathies

A group of rare genetic disorders caused by mutations in the RAS/MAPK signaling pathway, often associated with developmental abnormalities and increased cancer risk. (Pasithea is targeting PAS-004 for RASopathies, indicating a focus on a specific area of genetic disease with potential for therapeutic intervention.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial offering, there is no prior comparable filing to assess year-over-year changes in revenue, margins, or financial metrics. The filing primarily serves to introduce the company's business, strategy, and risks to potential investors.

Key Financial Figures

• $0.0001 — 0 shares of our common stock, par value $0.0001 per share. The assumed public offering
• $0.80 — price for each share of common stock is $0.80. We are also offering pre-funded warr
• $0.001 — of common stock at an exercise price of $0.001 per share. The assumed public offering
• $0 — ice for each such Pre-Funded Warrant is $0.799, which is equal to the assumed publ
• $0.4876 — price of our common stock on Nasdaq was $0.4876 per share. However, all share and Pre-F
• $0.799 — c offering price of $0.80 per share and $0.799 per Pre-Funded Warrant. There is no est
• $1.00 — rants), at an assumed exercise price of $1.00 per share, which represents 125% of the
• $1 million — l Trial Award grant worth approximately $1 million to study PAS-004 in ALS patients. The a
• $1.40 — ur common stock at an exercise price of $1.40 per share, and (iv) Series D warrants t
• $1 — mon stock and accompanying warrants was $1.40, and the combined public offering pr
• $1.399 — d warrant and accompanying warrants was $1.399. Aggregate gross proceeds from the May
• $5.0 million — 2025 Public Offering were approximately $5.0 million. Simultaneously with the closing of the

Filing Documents

• ea0267537-s1a1_pasithea.htm (S-1/A) — 312KB
• ea026753701ex4-15_pasithea.htm (EX-4.15) — 106KB
• ea026753701ex5-1_pasithea.htm (EX-5.1) — 11KB
• ea026753701ex10-16_pasithea.htm (EX-10.16) — 214KB
• ea026753701ex23-1_pasithea.htm (EX-23.1) — 2KB
• ea026753701ex-fee_pasithea.htm (EX-FILING FEES) — 20KB
• image_001.jpg (GRAPHIC) — 7KB
• image_002.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 12KB
• ex5-1_002.jpg (GRAPHIC) — 15KB
• ex23-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-115595.txt ( ) — 865KB
• ea026753701ex-fee_pasithea_htm.xml (XML) — 9KB

USE OF PROCEEDS

USE OF PROCEEDS 10

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 12

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 15 PLAN OF DISTRIBUTION 16 INFORMATION INCORPORATED BY REFERENCE 19 WHERE YOU CAN FIND MORE INFORMATION 20 LEGAL MATTERS 20 EXPERTS 20 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Information Incorporated by Reference,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed

View Full Filing

View this S-1/A filing on SEC EDGAR